BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
BeiGene Ltd ADR BGNE
News
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene Announces Updates to Commercial Leadership Team
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
BeiGene Names Rosenberg Finance Chief as Wang Departs
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
BeiGene Shares Rise on First Dosing of Brukinsa
BeiGene Trial of Lung-Cancer Treatment Reaches Primary Endpoints
BeiGene Brukinsa Recommended for Approval From European Medicines Agency Committee
United States